Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2024 · View financials
Decision snapshot: UHAL stock price vs ITCI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ITCI's multiple
Needs ITCI P/E.
Implied fair value · at UHAL's multiple
Needs EPS (TTM) is negative, UHAL P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: UHAL FY 2026 (ended Mar 31, 2026) · ITCI FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
U-Haul Holding Company · implied price per share
Bear
$279.63
Base
$328.98
Bull
$378.33
Intra-Cellular Therapies, Inc. · implied price per share
Bear
-$2.92
Base
-$3.43
Bull
-$3.95
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.06x
0.19x
Net debt / EBITDA
Leverage against operating earnings
4.14x
9.34x
Cash and equivalents
Liquid reserves on the balance sheet
$1.14B
$904.35M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
RUSH ENTERPRISES INC \TX\
UHAL vs RUSHA
AVIS BUDGET GROUP, INC.
UHAL vs CAR
HERTZ GLOBAL HOLDINGS, INC
UHAL vs HTZ
RYDER SYSTEM INC
UHAL vs R
SUPERNUS PHARMACEUTICALS, INC.
UHAL vs SUPN
ACADIA PHARMACEUTICALS INC
UHAL vs ACAD
Vanda Pharmaceuticals Inc.
UHAL vs VNDA
Sage Therapeutics, Inc.
UHAL vs SAGE
$8.08B
$216.02M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
Live quote
